Press Releases

PreciThera, Inc. Completes $36 Million Series A Financing

MONTREAL, July 27, 2017 - PreciThera, Inc. a privately-held, precision medicine company, dedicated to the design and development of innovative biological therapeutics for the treatment of orphan bone diseases, today announced the completion of a Series A Financing of CAD$36 million (US$29 million). Investors participating in the financing include Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, CTI Life Sciences and Emerillon Capital.

Emerillon Capital and Sanderling Ventures Join Forces Backing a New Precision Medicine Company Based in Montreal, Canada

Montreal, May 10th 2017, Emerillon Capital and Sanderling Ventures announced they are joining forces to finance PreciThera Inc, an emerging Montreal based precision medicine company dedicated to the design and the development of innovative biological agents for the treatment of orphan diseases. PreciThera was recently founded by two internationally renowned scientists and successful entrepreneurs, Drs. Philippe Crine and Susan Schiavi. This initial financing is aimed at launching the company and securing a significant Series A round with several top tier Canadian and foreign investors.